Most of our understanding regarding the cellular reservoirs that maintain viral persistence has been derived from studies with lymphocytes. In contrast, the role played by myeloid-lineage cells (e.g., monocyte/macrophage and dendritic cells) in viral replication and persistence is not well understood. Our ongoing studies indicate that primate lentiviruses have evolved functions that specifically allow them to establish persistent reservoirs within myeloid-lineage cells. As the field now explores strategies that attempt to eradicate the virus from infected individuals, an understanding of the role played by myeloid-lineage cells in viral replication and persistence is essential. In this Project, we propose experiments that will define the role for macrophages in viral persistence and that will explore a strategy for removal of this potential viral reservoir in vivo. Our broadly-defined objectives are to define the mechanisms whereby HIV persists in macrophages (focusing on an HIV-induced survival pathway mediated by monocyte colony stimulating factor, or MCSF) and to define with precision the geospatial distribution of latently-infected cells in optimally treated hosts.
In Aim 1, we will determine the molecular mechanisms of macrophage latency as well as a strategy to interrupt this mechanism. We will also characterize the impact of MCSF and MCSF antagonists on chronic/latent infection of macrophage in vitro. This information will guide a strategy to purge infected macrophage in vivo (Aim 3 and Project 1).
In Aim 2, we will determine whether macrophages maintain viral persistence in the face of antiretroviral suppression. More specifically, we will characterize the viral genomes in tissue macrophages isolated from lymph node and gut-associated lymphoid tissue of patients on suppressive ART (with Project 6) and we will exploit the non-human primate model to extend our sampling of tissue macrophages into compartments not readily accessible in HIV-infected patients (with Project 1). Finally, in Aim 3, we will test strategies to purge infected macrophage in non-human primates. In direct association with analogous studies carried out in Project 1, we will examine whether MCSF antagonism eradicates SIV from the macrophage reservoir of the non-human primate.

Public Health Relevance

To attain the goal of viral eradication, an understanding of the reservoirs that allow HIV to persist in the face of therapy is essential. We hypothesize that, during suppressive ART, HIV establishes latent/chronic infection of T-cells and myeloid cells (especially macrophages) and that these reservoirs are a barrier to viral eradication. We will establish a role for myeloid cells in viral persistence during ART and develop a strategy to purge myeloid cell reservoirs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096109-02
Application #
8376032
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$707,658
Indirect Cost
$117,761
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Tjiam, M Christian; Morshidi, Mazmah A; Sariputra, Lucy et al. (2017) Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers. J Acquir Immune Defic Syndr 76:e90-e92
Martin, Alyssa R; Pollack, Ross A; Capoferri, Adam et al. (2017) Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J Clin Invest 127:651-656
Power, Jennifer; Fileborn, Bianca; Dowsett, Gary W et al. (2017) HIV cure research: print and online media reporting in Australia. J Virus Erad 3:229-235
Winckelmann, Anni; Barton, Kirston; Hiener, Bonnie et al. (2017) Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations. AIDS :
Mota, Talia M; Rasmussen, Thomas A; Rhodes, Ajantha et al. (2017) No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. AIDS 31:1137-1141
Rasmussen, Thomas A; Anderson, Jenny L; Wightman, Fiona et al. (2017) Cancer therapies in HIV cure research. Curr Opin HIV AIDS 12:96-104
Kaiser, Philipp; Joshi, Sunil K; Kim, Peggy et al. (2017) Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. J Virol Methods 242:1-8
Symons, Jori; Chopra, Abha; Malatinkova, Eva et al. (2017) HIV integration sites in latently infected cell lines: evidence of ongoing replication. Retrovirology 14:2
Tauriainen, Johanna; Scharf, Lydia; Frederiksen, Juliet et al. (2017) Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep 7:40354
Seang, Sophie; Somasunderam, Anoma; Nigalye, Maitreyee et al. (2017) Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection. Pathog Immun 2:239-252

Showing the most recent 10 out of 158 publications